Drug discontinuation was due to progression of disease in 10 patients (83%); grade 3 ALT/AST begins on the 3rd cycle of treatment in 1 patient (8%), and grade 2 vomiting and grade 2 dyspnea (unrelated) is followed by rapid clinical deterioration due to pleural effusion in 1 patient (8%). This evidence concerns the gene GPT and Pleural effusion.